Hyperlipoproteinemia Type V

A severe type of hyperlipidemia, sometimes familial, that is characterized by the elevation of both plasma CHYLOMICRONS and TRIGLYCERIDES contained in VERY-LOW-DENSITY LIPOPROTEINS. Type V hyperlipoproteinemia is often associated with DIABETES MELLITUS and is not caused by reduced LIPOPROTEIN LIPASE activity as in HYPERLIPOPROTEINEMIA TYPE I .

Also Known As:

Hyperchylomicronemia Late Onset; Hyperchylomicronemia With Hyperprebetalipoproteinemia, Familial; Hyperchylomicronemia, Late-Onset; Hyperlipemia, Combined Fat And Carbohydrate-Induced; Hyperlipemia, Mixed; Hyperlipidemia, Type V; Hyperlipoproteinemia Type 5; Hyperlipoproteinemia, Type V; Hyperchylomicronemia Late Onsets; Hyperchylomicronemia, Late Onset; Hyperchylomicronemias, Late-Onset; Hyperlipemia, Combined Fat And Carbohydrate Induced; Hyperlipemias, Mixed; Hyperlipidemias, Type V; Hyperlipoproteinemia Type 5s; Hyperlipoproteinemias, Type V; Late-Onset Hyperchylomicronemia; Late-Onset Hyperchylomicronemias; Mixed Hyperlipemia; Mixed Hyperlipemias; Type V Hyperlipidemia; Type V Hyperlipidemias; Type V Hyperlipoproteinemia; Type V Hyperlipoproteinemias

Networked: 101 relevant articles (0 outcomes, 9 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Hyperlipidemias (Hyperlipidemia)
2.	Xanthomatosis (Xanthoma)
3.	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
4.	Hypertriglyceridemia
5.	Pancreatitis

Experts

1.	Yamashita, Shizuya: 2 articles (09/2013 - 01/2012)
2.	Ishibashi, Shun: 2 articles (01/2012 - 11/2005)
3.	Kobayashi, Junji: 2 articles (01/2012 - 06/2005)
4.	Moulin, Philippe: 2 articles (02/2010 - 10/2005)
5.	Sassolas, Agnès: 2 articles (02/2010 - 10/2005)
6.	Abe, Taro: 1 article (04/2022)
7.	Kokutou, Hiroyuki: 1 article (04/2022)
8.	Morimoto, Kozo: 1 article (04/2022)
9.	Ohta, Ken: 1 article (04/2022)
10.	Shimoda, Masafumi: 1 article (04/2022)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hyperlipoproteinemia Type V:

1.	LipidsIBA 02/01/1975 - "Studies of adipocyte metabolism were performed in twelve male subjects with normal plasma lipids and eleven male patients with Type IV or Type V hyperlipoproteinemia. " 07/01/2023 - "Type V hyperlipoproteinemia or multifactorial chylomicronemia syndrome is a rare lipid disorder triggered mainly by uncontrolled diabetes, obesity, poor diet, or particular medications. " 03/01/2001 - "To better characterize the interaction between fasting and postprandial lipid profile after menopause, we examined postprandial changes in several lipid parameters in three age-matched groups of postmenopausal women (16 affected by mixed hyperlipemia, 17 by common hypercholesterolemia, and 17 normolipemic), who underwent a standardized oral fat-loading test. " 01/18/1979 - "These differences suggest that the agglutination phenomenon is in relation with the nature of the lipid particles present in the hyperlipidemic sera, which could be "chylomicron remnants" in type V hyperlipidemias, and other forms of "remnants" in type IV and IIb hyperlipidemias. " 10/01/1978 - "These differences suggest that the agglutination phenomenon is in relation with the nature of the lipid particles present in the hyperlipidemic sera, which could be "chylomicron remnants" in type V hyperlipidemias, and other forms of "remnants" in type IV and IIb hyperlipidemias. "
2.	Triglycerides (Triacylglycerol)IBA 01/01/1987 - "Hyperlipoproteinemia type V, with serum triglyceride concentrations of about 20 mmol/l, was detected in a pair of monozygotic, 40-year-old twin brothers. " 11/07/2023 - "However, middle-grade proteinuria and increased serum triglyceride levels indicative of type V hyperlipidemia developed rapidly thereafter. " 09/01/1993 - "At the age of 18 years, grossly elevated cholesterol and triglyceride levels were documented and type V hyperlipidemia was diagnosed. " 07/01/1993 - "Patients with hypertriglyceridemia (triglyceride level more than 2,200 mg/liter)--14 patients with diabetes and 12 with type V hyperlipoproteinemia--were compared with age- and sex-matched control subjects. " 01/01/2001 - "In patients with type V hyperlipidemia SLC maximal velocity correlated with log triglycerides (r2 = 0.853; P < .001) and log very low-density lipoprotein (VLDL) triglycerides (r2 = 0.947; P < .001). "
3.	Lipoproteins (Lipoprotein)IBA 11/01/1985 - "This study indicates plasma lipoprotein abnormalities in Type V hyperlipoproteinemia and may suggest that depressed platelet aggregation and release in these patients are a result of this normal lipoprotein pattern." 05/01/2023 - "The electrophoretic pattern of lipoprotein was consistent with type V hyperlipoproteinemia. " 11/01/1985 - "Plasma lipoprotein pattern and decreased platelet function in type V hyperlipoproteinemia." 11/01/1977 - "The clinical presentation, metabolic associations, and natural history confirm the distinctiveness of primary type V hyperlipoproteinemia from other lipoprotein abnormalities. " 11/01/1976 - "Of the 285 patients investigated, 280 were classified as having lipoprotein patterns of type IIa (117), IIb (90) or IV (73); two patients had type III; and three patients had type V hyperlipoproteinemia. "
4.	VLDL LipoproteinsIBA 04/10/1971 - "[Study of mixed hyperlipemia with a distinct excess of beta and pre-beta lipoproteins (78 cases)]." 04/01/1971 - "[On mixed hyperlipemia with distinct accumulation of beta- and pre-beta- lipoproteins. " 01/01/1971 - "[Mixed hyperlipemia with a distinct accumulation of beta and prebeta lipoproteins (apropos of 78 cases)]." 11/01/2005 - "Based on the increase in the concentrations of both chylomicrons and very low density lipoproteins, type V hyperlipoproteinemia was diagnosed. " 01/01/2001 - "In patients with type V hyperlipidemia SLC maximal velocity correlated with log triglycerides (r2 = 0.853; P < .001) and log very low-density lipoprotein (VLDL) triglycerides (r2 = 0.947; P < .001). "
5.	Insulin (Novolin)FDA Link 07/01/2023 - "A Case of Type V Hyperlipoproteinemia Resistant to Insulin Treatment." 08/01/1997 - "Though her insulin secretory activity was preserved, she fell into mild diabetic ketoacidosis (DKA) and showed type V hyperlipidemia. " 01/01/1975 - "A case of xanthomatosis and hyperlipoproteinemia type V propably induced by overdosage of insulin." 01/15/1999 - "One subtype, familial partial lipodystrophy Dunnigan (FPLD), is a rare autosomal dominant trait that results in an gradual loss of subcutaneous fat in the lower trunk and limbs, Type V hyperlipoproteinemia, hypertriglyceridemia, and insulin-resistant diabetes. " 03/01/2001 - "The magnitude of postprandial lipemia, expressed as 8-hour triglyceride incremental area under the curve, was greater in women with mixed hyperlipemia (1,326 +/- 372 mg x dL(-1) x h(-1)) than in normal (484 +/- 384 mg x dL(-1) x h(-1)) and hypercholesterolemic (473 +/- 223 mg x dL(-1) x h(-1); both P <.0001) women, and the differences held after adjustment for body mass index and fasting insulin. "
6.	Glucose (Dextrose)FDA LinkGeneric 09/01/1983 - "The patient exhibited insulin resistance, carbohydrate intolerance, striking fasting- and glucose-stimulated hyperinsulinemia, hyperglucagonemia, type V hyperlipoproteinemia, and lipoprotein lipase deficiency on a normal diet. " 12/05/1977 - "Metabolic studies of a 9-year-old girl with primary type V hyperlipoproteinemia demonstrated normal glucose tolerance, plasma insulin and glucagon responses to stimuli, and serum uric acid level. " 01/01/2001 - "Patients with type V hyperlipidemia were normotensive but more obese than controls, had elevated triglycerides, very low-density lipoprotein, glucose, and insulin; and reduced HDL cholesterol compared with type IIb controls. "
7.	Fish OilsIBA 06/14/1993 - "Moreover, fish oil may prevent the "chylomicronemia" syndrome of type V hyperlipidemia." 01/01/1990 - "Fish oil may have promise as a therapeutic agent in certain hyperlipidemic states, especially the chylomicronemia of type V hyperlipidemia. " 07/01/1988 - "In the experimental studies reported in this review, dietary omega-3 fatty acids from fish and fish oil had profound hypolipidemic effects in normal subjects and in hypertriglyceridemic patients with combined hyperlipidemia (type IIb) and type V hyperlipidemia. "
8.	Clofibrate FDA Link 02/01/1984 - "[Electron microscopic studies of eruptive xanthomas with type V hyperlipoproteinemia, in regressing stage of xanthoma by clofibrate therapy]." 09/01/1982 - "4. Preferred indications of clofibrate therapy are hypertriglyceridemias in type IIb, type III, type IV, and type V hyperlipoproteinemia (in combination with other pharmaceuticals) and refractory hypercholesterolemias in type IIa and type IIb hyperlipoproteinemia." 04/17/1977 - "[Clofibrate action on the lipoprotein composition in primary type IV and type V hyperlipoproteinemia]."
9.	Apolipoprotein A-VIBA 09/01/2016 - "We report a novel homozygous apolipoprotein A5 (APOA5) frameshift mutation (c.G425del-C, p.Arg143AlafsTer57) identified in a 12-year-old boy of Pakistani origin with severe hypertriglyceridemia (up to 35 mmol/L) and type V hyperlipoproteinemia. " 04/01/2006 - "The sequencing of the APOA5 gene in patients with primary hypertriglyceridemia, in whom mutations of the LPL and APOC2 genes had been excluded, led to the identification of four families with two different mutations in this gene predicted to result in truncated apolipoprotein A-V. The first mutation (Q148X) was found in a homozygous state in a child with severe type V hyperlipidemia, some clinical manifestations of chylomicronemia syndrome and a slight reduction in plasma postheparin lipoprotein lipase activity. " 10/01/2006 - "The relevance of apolipoprotein A-V (apoA-V) for human lipid homeostasis is underscored by genetic association studies and the identification of truncation-causing mutations in the APOA5 gene as a cause of type V hyperlipidemia, compatible with an LPL-activating role of apoA-V. An inverse correlation between plasma apoA-V and triglyceride (TG) levels has been surmised from animal data. " 04/01/2006 - "Mutations in the APOA5 gene, leading to truncated apolipoprotein A-V devoid of lipid-binding domains located in the carboxy-terminal end of the protein, if present in the homozygous state, are expected to cause severe type V hyperlipidemia in patients with no mutations in LPL or APOC2 genes. "
10.	EnzymesIBA 12/18/1980 - "Furthermore the laboratory studies showed a hyperlipidemia (type V) and an increase in pancreatic enzymes. " 12/01/1983 - "Results of lipid and enzyme analysis of the subcutaneous xanthoma were similar to those of xanthomas derived from a patient with diabetes mellitus and type V hyperlipidemia. "

Therapies and Procedures

1.	Therapeutics 01/01/2009 - "We here report our results of long-term treatment of hyperTG in 6 patients with Frederickson Type V hyperlipidemia who had recurrent attacks of pancreatitis due to hyperTG refractory to medical therapy. " 07/01/1990 - "Does Dietary Therapy for Hyperlipoproteinemia Type V Predispose to Premature Atherosclerosis?" 02/01/1984 - "[Electron microscopic studies of eruptive xanthomas with type V hyperlipoproteinemia, in regressing stage of xanthoma by clofibrate therapy]." 03/01/1987 - "A patient with severe type V hyperlipoproteinemia and chronic end-stage renal disease received a renal transplant and therapy with cyclosporine. " 12/01/1986 - "A 48-year-old woman with malabsorption and type V hyperlipoproteinemia developed hypervitaminosis A with a total plasma vitamin A level of 871 micrograms/dL during therapy with an oral dosage of 18,000 retinol equivalents (60,000 IU) daily. "
2.	Renal Dialysis (Hemodialysis) 01/01/1991 - "A patient with type V hyperlipoproteinemia on hemodialysis, a patient with type IIa homozygous, and a patient with type IIa heterozygous familial hypercholesterolemia were used in this study. "
3.	Fat-Restricted Diet (Diet, Fat Restricted) 07/01/1990 - "The patient described in this case report had typical clinical and biochemical features of type V hyperlipoproteinemia and was treated with a low-fat diet that led to abolishment of chylomicronemia, a decrease in plasma triglycerides, and an increase in low-density lipoprotein cholesterol. "
4.	Plasmapheresis 05/01/1987 - "Type V hyperlipoproteinemia and plasmapheresis."
5.	Laparotomy 01/01/1981 - "Acute pancreatitis verified at laparotomy occurred in the 37th week in 1 of 4 women who developed excessive hypertriglyceridemia (type V hyperlipoproteinemia) during pregnancy. "